Ilhan Aysegul, Gartner Wolfgang, Neziri Dashurie, Czech Thomas, Base Wolfgang, Hörl Walter H, Wagner Ludwig
Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria.
Anticancer Res. 2009 Feb;29(2):731-6.
Angiopoiesis and angiopoietic growth factors are of considerable importance in the development and progression of intracranial tumours. However, knowledge of the plasma detectability of distinct angiogenic factors in patients with brain tumour is very limited. This study evaluates the plasma concentrations of the angiogenic factors angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF) and platelet-derived growth factor BB (PDGF-BB) in patients with brain tumour.
Plasma samples of 78 patients suffering from various types of intracranial tumours (glioblastoma multiforme, GBM, n = 22; astrocytoma, n = 12; meningioma, n = 16; and intracranial metastasis, n = 28) were analysed. For determination of plasma concentrations of angiogenic factor, highly specific enzyme-linked immuno sorbent assays (ELISAs) were used.
Ang-2 plasma concentration in GBM patients was significantly lower when compared with that in patients with meningioma and intracranial metastasis. Highest levels of VEGF concentrations were detected in plasma derived from patients suffering from meningioma. Interestingly, VEGF plasma levels depended on the number of intracranial lesions, with significantly higher concentrations in patients with 3 or more lesions when compared with those with 2 or fewer lesions. However, no correlation between the survival time of the patients and the plasma levels of the tested growth factors was obtained. Plasma levels of PDGF-BB did not differ between the individual tumour groups.
The detectability of the angiogenic factors Ang-2 and VEGF, as well as of PDGF-BB, in the plasma of patients suffering from various types of brain tumours is described. The plasma detectability of the individual angiopoetic factors seems to depend at least partly on the tumour type as well as on tumour progression. This might be of prognostic and therapeutic relevance.
血管生成及血管生成生长因子在颅内肿瘤的发生和发展中具有相当重要的意义。然而，关于脑肿瘤患者中不同血管生成因子的血浆可检测性的知识非常有限。本研究评估了脑肿瘤患者血浆中血管生成因子血管生成素-2（Ang-2）、血管内皮生长因子（VEGF）和血小板衍生生长因子BB（PDGF-BB）的浓度。
分析了78例患有各种类型颅内肿瘤（多形性胶质母细胞瘤，GBM，n = 22；星形细胞瘤，n = 12；脑膜瘤，n = 16；颅内转移瘤，n = 28）患者的血浆样本。为了测定血管生成因子的血浆浓度，使用了高度特异性的酶联免疫吸附测定（ELISA）。
与脑膜瘤和颅内转移瘤患者相比，GBM患者的Ang-2血浆浓度显著降低。在脑膜瘤患者的血浆中检测到最高水平的VEGF浓度。有趣的是，VEGF血浆水平取决于颅内病变的数量，与有2个或更少病变的患者相比，有3个或更多病变的患者血浆浓度显著更高。然而，未发现患者的生存时间与所检测生长因子的血浆水平之间存在相关性。各肿瘤组之间PDGF-BB的血浆水平没有差异。
描述了患有各种类型脑肿瘤患者血浆中血管生成因子Ang-2、VEGF以及PDGF-BB的可检测性。各个血管生成因子的血浆可检测性似乎至少部分取决于肿瘤类型以及肿瘤进展情况。这可能具有预后和治疗相关性。
